Eric Easom - 23 Feb 2023 Form 4 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Chief Executive Officer, Director
Signature
/s/ Lucy Day, Attorney-in-Fact for Eric Easom
Issuer symbol
ANTX
Transactions as of
23 Feb 2023
Net transactions value
$0
Form type
4
Filing time
24 Feb 2023, 16:36:06 UTC
Previous filing
14 Nov 2022
Next filing
15 May 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ANTX Stock Option (right to buy) Award $0 +267,650 $0.000000 267,650 23 Feb 2023 Common Stock 267,650 $11.99 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option vest as follows: 1/48 of the shares shall vest on each monthly anniversary as measured from January 1, 2023.